Hypera (HYPE3) Q2 2024 earnings summary

Executive summary

• Sell-out increased 6.3% in Q2 2024, driven by chronic and preventive treatments, with a robust innovation pipeline and new product launches strengthening the portfolio.

• Net revenue for Q2 2024 reached R$2,188.9 million, down 1.9% year-over-year, while net income from continuing operations was R$491.8 million, a 2.5% decrease.

• Record operating cash flow of R$624.2 million, up 8.0% from 2Q23, supported by inventory reduction.

• Interest on capital of R$184.9 million (R$0.29 per share) approved in the quarter.

• Selected again for the FTSE4Good Index Series and published the 2023 annual report aligned with global ESG standards.

Financial highlights

• Net revenue for H1 2024 exceeded R$4 billion, representing 47% of annual guidance.

• EBITDA margin from continuing operations was 34.5%, down 0.9 p.p. year-over-year, with gross margin at 60.9% due to product mix and higher discounts.

• Free cash flow reached R$458.9 million in Q2 2024, up R$113.8 million year-over-year.

• EPS at R$0.78, a 1.9% decrease from 2Q23.

• Marketing expenses ranged from 15.2% to 22% of net revenue, with flexibility by segment.

Outlook and guidance

• 2024 net revenue guidance is R$8.6 billion, with EBITDA expected at R$3.0 billion and net profit at R$1.85 billion.

• Confident in achieving 2024 guidance, expecting higher sell-out in H2 as influenza market recovers post-El Niño.

• Innovation pipeline focused on chronic/preventive treatments, expected to outpace market growth over the next five years.

• Focus remains on reducing inventories to drive operating and free cash flow growth.